| scholarly article | Q13442814 |
| P50 | author | Jacek Jassem | Q19690551 |
| Salvatore Siena | Q28321703 | ||
| Josep Tabernero Caturla | Q37387600 | ||
| David Cunningham | Q38803238 | ||
| György Bodoky | Q46772644 | ||
| Martin Šmakal | Q57963303 | ||
| P2093 | author name string | F Xu | |
| F Rivera | |||
| J Cassidy | |||
| Y Tian | |||
| Y Humblet | |||
| J Y Douillard | |||
| J L Canon | |||
| P Ruff | |||
| M Rother | |||
| R Burkes | |||
| R Sidhu | |||
| M Błasińska-Morawiec | |||
| I Kocákova | |||
| K S Oliner | |||
| M Barugel | |||
| P433 | issue | 7 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 1346-1355 | |
| P577 | publication date | 2014-04-08 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer | |
| P478 | volume | 25 |
| Q36211003 | 2011 update in gastrointestinal cancer therapeutics |
| Q41918758 | A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer |
| Q38674714 | A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer |
| Q38828343 | A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. |
| Q35194602 | A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer |
| Q37352435 | A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy |
| Q90115442 | A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer |
| Q47138214 | AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer |
| Q49951874 | Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. |
| Q53402902 | Adverse kidney effects of epidermal growth factor receptor inhibitors |
| Q50041173 | An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma |
| Q40507543 | Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients |
| Q41275180 | Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma |
| Q42281334 | Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. |
| Q49771879 | BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. |
| Q52657104 | Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis |
| Q47635827 | Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. |
| Q42933363 | Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer |
| Q38792685 | Characterization of novel low passage primary and metastatic colorectal cancer cell lines |
| Q38375059 | Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. |
| Q55003485 | Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. |
| Q28073730 | Clinical applications of liquid biopsies in gastrointestinal oncology |
| Q92706903 | Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
| Q47682948 | Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue |
| Q47984460 | Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. |
| Q64229063 | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| Q53482447 | Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations |
| Q38644154 | Combination Adjuvant Chemotherapy with Targeted Drugs for Treatment of Colorectal Cancer: A Network Meta-Analysis. |
| Q36257068 | Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma |
| Q99605181 | Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments |
| Q46185591 | Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. |
| Q39704299 | Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients |
| Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
| Q38860960 | Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer |
| Q38544945 | Cost Considerations in the Evaluation and Treatment of Colorectal Cancer |
| Q37564679 | Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism |
| Q38628257 | Current and advancing treatments for metastatic colorectal cancer |
| Q91830988 | Current and emerging biomarkers in metastatic colorectal cancer |
| Q38787244 | Current and future biomarkers in the treatment of colorectal cancer. |
| Q39172118 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie |
| Q38538213 | Current controversies in the management of metastatic colorectal cancer |
| Q90342567 | Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? |
| Q33898865 | Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. |
| Q90734623 | Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors |
| Q38814615 | Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund |
| Q47369045 | Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis |
| Q92040279 | Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan |
| Q92278652 | Durable complete response in a patient with metastatic left-sided colon cancer treated with 5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report |
| Q52677759 | Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. |
| Q37327850 | Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial |
| Q37235153 | Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis |
| Q39694235 | Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis |
| Q47141058 | Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil |
| Q38666172 | Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. |
| Q92809360 | Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue |
| Q38872136 | Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. |
| Q34663697 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial |
| Q52627284 | FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer |
| Q64899523 | Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen. |
| Q90450020 | First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials |
| Q38638287 | First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 tri |
| Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
| Q45030051 | Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). |
| Q34482529 | How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer? |
| Q38826639 | How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials |
| Q27026516 | How to select the optimal treatment for first line metastatic colorectal cancer |
| Q47698425 | Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis. |
| Q98164811 | Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis |
| Q47137265 | KRAS biomarker testing disparities in colorectal cancer patients in New Mexico |
| Q37014304 | Last line therapy with sorafenib in colorectal cancer: A retrospective analysis |
| Q37687034 | Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. |
| Q37687424 | Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation |
| Q26823550 | Management of colorectal cancer |
| Q59803127 | Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy |
| Q38938329 | Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. |
| Q35761956 | Molecular markers predictive of chemotherapy response in colorectal cancer |
| Q26785725 | Molecular phenotypes of colorectal cancer and potential clinical applications |
| Q26778296 | Molecular profiling in the treatment of colorectal cancer: focus on regorafenib |
| Q38253815 | Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. |
| Q35213124 | Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer |
| Q35686487 | Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial |
| Q36343047 | Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents |
| Q33774917 | New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury |
| Q26796348 | New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q90056572 | Objective response rate assessment in oncology: Current situation and future expectations |
| Q39017641 | On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis |
| Q38684918 | Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis |
| Q100455818 | Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment |
| Q34528276 | Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer. |
| Q90277210 | Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System |
| Q61816598 | Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib |
| Q88288687 | Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment |
| Q28082816 | Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status |
| Q38296666 | Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement |
| Q51507476 | Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors |
| Q92618103 | Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rati |
| Q36201465 | Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer |
| Q36750569 | Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer |
| Q35766292 | Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study |
| Q38805790 | Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer |
| Q26771952 | Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer |
| Q38582586 | Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. |
| Q40243706 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. |
| Q34703562 | Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer |
| Q54889286 | Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. |
| Q50048719 | RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment |
| Q57162471 | RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine |
| Q41105389 | Recent developments in the treatment of metastatic colorectal cancer. |
| Q37496672 | Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors |
| Q38326113 | Regulatory considerations for companion diagnostic devices |
| Q35810693 | Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response |
| Q89793537 | Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer |
| Q91672103 | Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population |
| Q48226075 | Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. |
| Q49566155 | Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials |
| Q90627128 | SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018) |
| Q35230366 | Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer |
| Q35183695 | Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014 |
| Q26751035 | Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy |
| Q33432141 | Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer |
| Q50872828 | Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety |
| Q36167042 | Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. |
| Q35764163 | Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach |
| Q48512300 | Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer |
| Q41953360 | Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab |
| Q41307728 | Successful treatment with s-1 and oxaliplatin combination therapy in an elderly patient with metastatic colorectal cancer initially presenting with membranous nephropathy |
| Q39996371 | Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. |
| Q89514592 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial |
| Q39949794 | Systemic treatment of liver metastases from colorectal cancer |
| Q38961110 | Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. |
| Q92306520 | Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review |
| Q42371654 | Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis |
| Q30862367 | Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data |
| Q92747984 | Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer |
| Q37204270 | Targeted therapy in cancer |
| Q39163561 | Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. |
| Q56965763 | Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer |
| Q41878988 | The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences |
| Q34648886 | The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
| Q38481038 | The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors |
| Q42522992 | The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials |
| Q90352590 | The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies |
| Q92462230 | The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer |
| Q104111202 | The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis |
| Q38776999 | The safety of monoclonal antibodies for treatment of colorectal cancer |
| Q38268569 | The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective? |
| Q26775522 | Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review |
| Q26776215 | Treatment Individualization in Colorectal Cancer |
| Q26781457 | Treatment of colorectal cancer in the elderly |
| Q55155497 | Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy. |
| Q38401605 | Tyrosine kinase-targeting drugs-associated heart failure |
| Q37361095 | Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy |
| Q90701649 | Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice |
| Q39910176 | Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab |
| Q38833684 | Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. |
Search more.